☆ 4.1 Article

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

REVUE NEUROLOGIQUE (2018)

Journal

REVUE NEUROLOGIQUE

Volume 174, Issue 4, Pages 255-264

Publisher

MASSON EDITEUR

DOI: 10.1016/j.neurol.2017.11.005

Keywords

Neuromyelitis optica; Rituximab; Guidelines; Recommendations; Treatment

Categories

Clinical Neurology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

There is growing evidence of a preventive effect of Rituximab (RTX) in neuromyelitis optica spectrum disorders (NMO-SD). This monoclonal antibody against CD20 is becoming the most widely used preventive therapy in NMO-SD, as a first-line therapy or as a rescue therapy. Nevertheless, considerable heterogeneity still exists concerning the pre-treatment work-up, the vaccinations required before and under treatment, the number and dosage of infusions, prevention of the risk of infusion-related reactions, prevention of infections under treatment, and frequency of therapeutic cycles. Thanks to a collaborative work among NMO-SD experts belonging to the NOMADMUS project, we provide here recommendations for all these topics concerning RTX use in NMO-SD. (C) 2018 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Clinical Neurology

Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder

Raffaella Pizzolato Umeton, Michael Waltz, Gregory S. Aaen, Leslie Benson, Mark Gorman, Manu Goyal, Jennifer S. Graves, Yolanda Harris, Lauren Krupp, Timothy E. Lotze, Nikita M. Shukla, Soe Mar, Jayne Ness, Mary Rensel, Teri Schreiner, Jan-Mendelt Tillema, Shelly Roalstad, Moses Rodriguez, John Rose, Emmanuelle Waubant, Bianca Weinstock-Guttman, Charles Casper, Tanuja Chitnis

Summary: This retrospective cohort study evaluated cases of children with NMOSD and found that the use of disease-modifying treatments, particularly rituximab, is associated with a lowered annualized relapse rate in children with NMOSD AQP4+.

NEUROLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Treatment of Neuromyelitis Optica Spectrum Disorders

Koon-Ho Chan, Chi-Yan Lee

Summary: NMOSD is an autoimmune disorder that predominantly affects females, leading to serious CNS inflammatory disorders. The pathogenesis involves AQP4-IgG autoantibodies targeting aquaporin-4, triggering astrocytopathy and neuroinflammation.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Clinical Neurology

Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder

Bingxin Shi, Mangsuo Zhao, Liyan Qiao, Fangjie Huang, Shimei Zhou, Yan Wei, Jing Wang

Summary: After rituximab treatment, some NMOSD patients may experience relapses shortly after initiation, with most relapses occurring after the initial use of rituximab. Clinical manifestations mainly include optic neuritis and myelitis, and low-dosage rituximab may still be effective.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Review Clinical Neurology

New therapies for neuromyelitis optica spectrum disorder

Michael Levy, Kazuo Fujihara, Jacqueline Palace

Summary: Neuromyelitis optica spectrum disorder is a rare autoimmune disease affecting the CNS, with recent trials showing benefits of new therapies in preventing future attacks. However, differences in efficacy, safety, tolerability, and practical considerations of these therapies may impact their use in real-world populations of patients. Future research should focus on unmet needs, including aquaporin-4 seronegative disease and treatments for acute relapses and recovery from autoimmune attacks in the CNS.

LANCET NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies

Su-Hyun Kim, Hyunmin Jang, Na Young Park, Yeseul Kim, So-Yeon Kim, Min Young Lee, Jae-Won Hyun, Ho Jin Kim

Summary: Discontinuation of IST in NMOSD patients may lead to an increased risk of relapse, even after 5 years of remission. Caution is advised when considering IST discontinuation, especially in patients who have experienced severe attacks prior to IST.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

Add to Collection

Article Clinical Neurology

Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder

Sean J. Pittock, Michael Barnett, Jeffrey L. Bennett, Achim Berthele, Jerome de Seze, Michael Levy, Ichiro Nakashima, Celia Oreja-Guevara, Jacqueline Palace, Friedemann Paul, Carlo Pozzilli, Marcus Yountz, Kerstin Allen, Yasmin Mashhoon, Ho Jin Kim

Summary: The CHAMPION-NMOSD study evaluated the efficacy and safety of ravulizumab in adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Ravulizumab, which has a longer half-life compared to eculizumab, significantly reduced relapse risk in these patients.

ANNALS OF NEUROLOGY (2023)

Add to Collection

Article Neurosciences

Immunobiology of neuromyelitis optica spectrum disorders

Daissy Liliana Mora Cuervo, Gisele Hansel, Douglas Kazutoshi Sato

Summary: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory disease that is characterized by the presence of autoantibodies targeting the water channel aquaporin-4 (AQP4-IgG). The core clinical manifestations of NMOSD include optic neuritis, longitudinally extensive myelitis, and area postrema syndrome. Diagnosis is based on clinical manifestations, magnetic resonance imaging findings, and the presence of AQP4-IgG. Recent advances in the understanding of NMOSD immunobiology have led to approved treatments such as eculizumab, satralizumab, and inebilizumab.

CURRENT OPINION IN NEUROBIOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Neuromyelitis Optica Spectrum Disorder

Dean M. Wingerchuk, Claudia F. Lucchinetti

Summary: Neuromyelitis Optica and its spectrum is a relapsing demyelinating disorder of the central nervous system, encompassing six syndromes and associated with aquaporin-4 autoantibodies. Effective treatment is able to prevent relapses.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

Neuromyelitis Optica Spectrum Disorder

Dean M. Wingerchuk, Claudia F. Lucchinetti

Summary: Neuromyelitis Optica, previously known as Devic's disease, is a relapsing demyelinating disorder of the central nervous system that encompasses six syndromes and is associated with aquaporin-4 autoantibodies. Effective treatment is crucial in preventing relapses.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Clinical Neurology

Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate

Yang Yang, Lifeng Chen, Lei Wu, Jiarui Yao, Na Wang, Xiaoqing Su, Dongmei Li, Lina Han, Weiping Wu, Dehui Huang, Tianyu Jiang, Zhenfu Wang

Summary: RTX, AZA, and MMF therapies were found to effectively reduce relapse frequency and disability in both AQP4-Ab seropositive or seronegative patients with NMO. Low dosage of RTX is recommended for NMO patients due to its long-term effectiveness and safety.

NEUROLOGY AND THERAPY (2022)

Add to Collection

Article Immunology

Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study

Daidi Zhao, Kaixi Ren, Jiarui Lu, Zhiqin Liu, Zunbo Li, Jun Wu, Zhihao Xu, Songdi Wu, Tao Lei, Chao Ma, Sijia Zhao, Miao Bai, Hongzeng Li, Jun Guo

Summary: This study evaluated the efficacy and safety of a lower-dose rituximab (RTX) therapy for neuromyelitis optica spectrum disorder (NMOSD) based on a multicenter, open-label, prospective follow-up study. The results demonstrated that the lower-dose RTX strategy significantly reduced relapse rate, improved disability score, and decreased spinal cord lesion. Early therapy initiation showed better outcomes compared to delayed therapy.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Immunology

Increased proportion of CD20+T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report

Jong Kwon Lee, Soonwook Kwon, Jung-Ho Han, Sang Eun Yoon, Byoung Joon Kim, Eun-Suk Kang

Summary: This study reported the detection of CD20+ T cells in an NMO patient treated with rituximab, who was later diagnosed with lung B-cell lymphoma. CD20+ T cells recovered faster than B cells after treatment and appeared to play a role in suppressing tumor growth and memory T cell activity.

JOURNAL OF NEUROIMMUNOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders

Valentina Damato, Jakob Theorell, Adam Al-Diwani, Anne-Kathrin Kienzler, Mateusz Makuch, Bo Sun, Adam Handel, Deniz Akdeniz, Antonio Berretta, Sudarshini Ramanathan, Andrew Fower, Daniel Whittam, Emily Gibbons, Nicholas McGlashan, Edward Green, Saif Huda, Mark Woodhall, Jacqueline Palace, Fintan Sheerin, Patrick Waters, Maria Leite, Anu Jacob, Sarosh R. Irani

Summary: This study reveals the relationship between clinical relapses and germinal center activity in patients with neuromyelitis optica spectrum disorders (NMOSDs), and shows that rituximab can suppress germinal center activity and reduce the production of AQP4 antibodies.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Add to Collection

Article Clinical Neurology

Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis

Shuo Zhao, Huanfen Zhou, Quangang Xu, Hong Dai, Shihui Wei

Summary: The study found that low-dose rituximab is significantly effective and well-tolerated in treating NMO-ON, reducing symptoms and improving vision stability or improvement in most patients during the follow-up period. High relapse-free rate was observed in patients who were followed up for over 12 months.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism

Ho Jin Kim, Orhan Aktas, Kristina R. Patterson, Schaun Korff, Amy Kunchok, Jeffrey L. Bennett, Brian G. Weinshenker, Friedemann Paul, Hans-Peter Hartung, Daniel Cimbora, Michael A. Smith, Nanette Mittereder, William A. Rees, Dewei She, Bruce A. C. Cree

Summary: The study shows similar clinical outcomes between NMOSD patients with F158 and V158 allele genotypes treated with approved Inebilizumab.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Add to Collection

Article Clinical Neurology

Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors

Xavier Boumaza, Baptiste Bonneau, Damien Roos-Weil, Carmela Pinnetti, Sebastian Rauer, Louisa Nitsch, Arnaud Del Bello, Ilijas Jelcic, Kurt-Wolfram Suehs, Jacques Gasnault, Yasemin Goreci, Oliver Grauer, Sharmilee Gnanapavan, Rebecca Wicklein, Nicolas Lambert, Thomas Perpoint, Martijn Beudel, David Clifford, Agnes Sommet, Irene Cortese, Guillaume Martin-Blondel

Summary: This study aimed to evaluate the real-world effectiveness of immune checkpoint inhibitors in the treatment of patients with progressive multifocal leukoencephalopathy (PML). Retrospective data from 79 PML patients who received immune checkpoint inhibitors were analyzed, and the results showed that mortality remained high and the development of inflammatory features or PML-IRIS was commonly observed. The study highlights the importance of personalized use of immune checkpoint inhibitors for PML patients.

ANNALS OF NEUROLOGY (2023)

Add to Collection

Review Clinical Neurology

Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society

Sandra Vukusic, Clarisse Carra-Dalliere, Jonathan Ciron, Elisabeth Maillart, Laure Michel, Emmanuelle Leray, Anne-Marie Guennoc, Bertrand Bourre, David Laplaud, Geraldine Androdias, Caroline Bensa, Kevin Bigaut, Damien Biotti, Pierre Branger, Olivier Casez, Mikael Cohen, Elodie Daval, Romain Deschamps, Cecile Donze, Anne-Laure Dubessy, Cecile Dulau, Francoise Durand-Dubief, Maxime Guillaume, Benjamin Hebant, Laurent Kremer, Arnaud Kwiatkowski, Julien Lannoy, Adil Maarouf, Eric Manchon, Guillaume Mathey, Xavier Moisset, Alexis Montcuquet, Julie Pique, Thomas Roux, Romain Marignier, Christine Lebrun-Frenay

Summary: The objective of this study was to develop evidence-based recommendations on pregnancy management for persons with multiple sclerosis (MS). A total of 104 proposed recommendations were reached through a thorough review of literature and expert consensus. These recommendations cover various aspects including pregnancy planning, follow-up, delivery routes, anesthesia, prevention of relapses, breastfeeding, vaccinations, etc. These recommendations are expected to harmonize counseling and treatment practices, and provide better and individualized choices for individuals with MS.

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Review Clinical Neurology

Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society

Sandra Vukusic, Romain Marignier, Jonathan Ciron, Bertrand Bourre, Mikael Cohen, Romain Deschamps, Maxime Guillaume, Laurent Kremer, Julie Pique, Clarisse Carra-Dalliere, Laure Michel, Emmanuelle Leray, Anne-Marie Guennoc, David Laplaud, Geraldine Androdias, Caroline Bensa, Kevin Bigaut, Damien Biotti, Pierre Branger, Olivier Casez, Elodie Daval, Cecile Donze, Anne-Laure Dubessy, Cecile Dulau, Francoise Durand-Dubief, Benjamin Hebant, Arnaud Kwiatkowski, Julien Lannoy, Adil Maarouf, Eric Manchon, Guillaume Mathey, Xavier Moisset, Alexis Montcuquet, Thomas Roux, Elisabeth Maillart, Christine Lebrun-Frenay

Summary: The French Multiple Sclerosis Society developed 66 specific evidence-based recommendations for pregnancy in women with NMOSD, covering various aspects such as pregnancy planning, antenatal and postnatal care, mode of delivery, relapse prevention, and more. These recommendations aim to harmonise counselling and treatment practice for better individualised choices by physicians and patients.

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Article Clinical Neurology

Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease

Clarisse Carra-Dalliere, Fabien Rollot, Romain Deschamps, Jonathan Ciron, Sandra Vukusic, Bertrand Audoin, Aurelie Ruet, Elisabeth Maillart, Caroline Papeix, Helene Zephir, David Laplaud, Mikael Cohen, Bertrand Bourre, Illiasse El-Bahi, Pierre Labauge, Romain Casey, Xavier Ayrignac, Romain Marignier

Summary: This study investigated the impact of pregnancy and post-partum on MOGAD activity and found a significant reduction in relapse rate during pregnancy and the post-partum period.

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Review Clinical Neurology

Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice

B. Bourre, O. Casez, J. Ciron, A. Gueguen, A. Kwiatkowski, X. Moisset, A. Montcuquet, X. Ayrignac

Summary: Multiple sclerosis (MS) is a common chronic inflammatory neurological disease, and the emergence of disease-modifying therapies (DMTs) has greatly improved disease control and disability progression in patients with MS. Personalized medicine aims to tailor treatment strategies to patients' characteristics, disease activity, and needs and preferences.

REVUE NEUROLOGIQUE (2023)

Add to Collection

Article Clinical Neurology

Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis A Large Multicenter Cohort Study

Michael Levraut, Sabine Laurent-Chabalier, Xavier Ayrignac, Kevin Bigaut, Manon Rival, Sanae Squalli, Helene Zephir, Tifanie Alberto, Jean-David Pekar, Jonathan Ciron, Damien Biotti, Benedicte Puissant-Lubrano, Jean-Philippe Camdessanche, Yannick Tholance, Olivier Casez, Bertrand Toussaint, Jeanne Marion, Thibault Moreau, Daniela Lakomy, Audrey Thomasset, Elisabeth Maillart, Delphine Sterlin, Aude Maurousset, Auriane Rocher, David Axel Laplaud, Edith Bigot-Corbel, Pierre-Olivier Bertho, Jean Pelletier, Joseph Boucraut, Pierre Labauge, Thierry Vincent, Jerome De Seze, Isabelle Jahn, Barbara Seitz-Polski, Eric Thouvenot, Christine Lebrun-Frenay

Summary: This study aimed to determine the diagnostic performances of kappa free light chains (KFLC) in diagnosing MS. The results showed that KFLC index and KFLC intrathecal fraction (IF) had similar performances in differentiating MS from other CNS disorders.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Add to Collection

Article Clinical Neurology

Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study

Mikael Cohen, Oceane Thomel-Rocchi, Aksel Siva, Darin T. Okuda, Rana Karabudak, Husnu Efendi, Murat Terzi, Clarisse Carra-Dalliere, Francoise Durand-Dubief, Eric Thouvenot, Jonathan Ciron, Helene Zephir, Bertrand Bourre, Olivier Casez, Jerome De Seze, Thibault Moreau, Jean-Philippe Neau, Daniel Pelletier, Orhun Kantarci, Melih Tutuncu, Nathalie Derache, Caroline Bensa, Celine Louapre, Jeanne Benoit, Cassandre Landes-Chateau, Christine Lebrun-Frenay

Summary: A study on individuals with radiologically isolated syndrome (RIS) found that COVID-19 vaccination or infection does not increase the risk of disease activity. Therefore, COVID-19 vaccination can be safely administered and repeated for these individuals.

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Article Clinical Neurology

Evaluation of risk management in a natalizumab home infusion procedure

J. -C. Lafontaine, J. Boucher, J. Giovannelli, J. Petit, O. Outteryck, S. Balagny, H. Zephir

Summary: The aim of this study is to describe and assess the safety of home infusion of natalizumab. The results indicate that the established home natalizumab procedure is safe using the university hospital home-care department.

REVUE NEUROLOGIQUE (2023)

Add to Collection

Article Clinical Neurology

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

Juliette Pelle, Anais R. Briant, Pierre Branger, Nathalie Derache, Charlotte Arnaud, Christine Lebrun-Frenay, Mikael Cohen, Lydiane Mondot, Jerome De Seze, Kevin Bigaut, Nicolas Collongues, Laurent Kremer, Damien Ricard, Flavie Bompaire, Charlotte Ohlmann, Magali Sallansonnet-Froment, Jonathan Ciron, Damien Biotti, Beatrice Pignolet, Jean-Jacques Parienti, Gilles Defer

Summary: A retrospective multicenter cohort study in France found that off-label extended interval dosing (EID) of natalizumab can effectively reduce the risk of progressive multifocal leukoencephalopathy (PML) in relapsing-remitting multiple sclerosis (RRMS) patients, and the risk of relapse is comparable to standard interval dosing (SID).

NEUROLOGY AND THERAPY (2023)

Add to Collection

Article Immunology

Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases

Xavier Boumaza, Margaux Lafaurie, Emmanuel Treiner, Ondine Walter, Gregory Pugnet, Guillaume Martin-Blondel, Damien Biotti, Jonathan Ciron, Arnaud Constantin, Marie Tauber, Florent Puisset, Guillaume Moulis, Laurent Alric, Yves Renaudineau, Dominique Chauveau, Laurent Sailler

Summary: We conducted a retrospective cohort study to assess the risk of severe infectious events in patients with autoimmune diseases who received rituximab treatment. The study found that the risk of severe infectious events was higher in patients with acquired hypogammaglobulinemia, lung disease, low gamma globulin levels, concomitant corticosteroid therapy, previous cyclophosphamide exposure, low lymphocyte count, and absence of pneumococcal vaccination. These findings can help guide clinical decision-making when considering rituximab treatment in immunosuppressed patients with hypogammaglobulinemia.

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

Add to Collection

Letter Clinical Neurology

Haemorrhagic myelitis as a manifestation of MOG antibody-associated disease

Jonathan Ciron, Damien Biotti, Chloe Bost, Fabrice Bonneville, Romain Marignier

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Add to Collection

Article Medicine, General & Internal

Training first-year medical residents to break bad news using healthcare role-play and trainees as simulated patients: Experience of the ADIAMED program from Lille University School of Medicine

P. Gagnerie, S. Sanges, P. Guerreschi, E. Wiel, G. Lebuffe, T. Sanctorum, M. Jourdain, S. Morell-Dubois, H. Zephir

Summary: Healthcare role-play is an interesting technique for training doctors to deliver bad news. Placing doctors in the roles of patients or relatives encourages reflection.

REVUE DE MEDECINE INTERNE (2023)

Add to Collection

Article Clinical Neurology

Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome The TERIS Randomized Clinical Trial

Christine Lebrun-Frenay, Aksel Siva, Maria Pia Sormani, Cassandre Landes-Chateau, Lydiane Mondot, Francesca Bovis, Patrick Vermersch, Caroline Papeix, Eric Thouvenot, Pierre Labauge, Francoise Durand-Dubief, Husnu Efendi, Emmanuelle Le Page, Murat Terzi, Nathalie Derache, Bertrand Bourre, Robert Hoepner, Rana Karabudak, Jerome De Seze, Jonathan Ciron, Pierre Clavelou, Sandrine Wiertlewski, Omer Faruk Turan, Nur Yucear, Mikael Cohen, Christina Azevedo, Orhun H. Kantarci, Darin T. Okuda, Daniel Pelletier, TERIS Study Grp

Summary: Radiologically isolated syndrome (RIS) is the earliest detectable preclinical phase of multiple sclerosis (MS) and can be identified through incidental magnetic resonance imaging (MRI) white matter anomalies. This study demonstrates that treatment with teriflunomide can delay the onset of symptoms consistent with MS. The results show that teriflunomide significantly reduces the risk of a first clinical demyelinating event in individuals with RIS.

JAMA NEUROLOGY (2023)

Add to Collection

Article Health Care Sciences & Services

Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study

Sarah Wilson, Floriane Calocer, Fabien Rollot, Mathieu Fauvernier, Laurent Remontet, Laure Tron, Sandra Vukusic, Emmanuelle Le Page, Marc Debouverie, Jonathan Ciron, Aurelie Ruet, Jerome De Seze, Helene Zephir, Thibault Moreau, Christine Lebrun-Frenay, David-Axel Laplaud, Pierre Clavelou, Pierre Labauge, Eric Berger, Jean Pelletier, Olivier Heinzlef, Eric Thouvenot, Jean Philippe Camdessanche, Emmanuelle Leray, Olivier Dejardin, Gilles Defer

Summary: This study examined the effects of socio-economic status on mortality in patients with multiple sclerosis. The findings showed that patients with lower socio-economic status had higher mortality rates. Therefore, improving overall care for multiple sclerosis patients with lower socio-economic status could help reduce socio-economic inequalities in disease-related mortality.

LANCET REGIONAL HEALTH-EUROPE (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.